{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010998","form_type":"8-K","ticker":null,"cik":"0001119643","company_name":"NUTRA PHARMA CORP","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.439595+00:00","generated_at":"2026-06-04T08:58:31.181077+00:00","sec_items":["5.02","8.01","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nutra Pharma CEO Rik Deitsch resigns amid SEC settlement; Dr. Michael Flax appointed CEO/CFO/Chairman","bullets":["Rik Deitsch resigned as CEO, Director, Chairman, and CFO effective March 19, 2024, due to SEC settlement.","SEC settlement permanently enjoins company, Deitsch, and McManus from securities law violations; 3-year officer/director and penny stock bars for Deitsch.","Disgorgement and civil penalties for all defendants, and a possible penny stock bar for McManus, left for later court resolution.","Dr. Michael Flax appointed CEO, CFO, and Chairman effective March 20, 2024; previously served as CEO of Nutra Pharma from 2001-2002.","Rik Deitsch remains as Operations Manager, reporting to VP of Operations Joe Lucas."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010998","json":"https://secwatch.observer/filing/0001493152-24-010998.json","markdown":"https://secwatch.observer/filing/0001493152-24-010998.md","text":"https://secwatch.observer/filing/0001493152-24-010998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1119643/000149315224010998/0001493152-24-010998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1119643/000149315224010998/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:58:31.181077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07cd6f8e2d","claim":"Rik J. Deitsch resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer at NUTRA PHARMA CORP.","evidence_excerpt":"On March 19, 2024, Mr. Deitsch submitted a letter of resignation to our Board of Directors and thereby resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer of Nutra Pharma Corp., effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1119643/000149315224010998/0001493152-24-010998-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"3a5fa0f056","claim":"Michael Flax was appointed as Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer at NUTRA PHARMA CORP.","evidence_excerpt":"On March 20, 2024, our Board of Directors unanimously approved of the appointment of Michael Flax, DDS as our Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1119643/000149315224010998/0001493152-24-010998-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}